*Candida glabrata* is an important fungal pathogen, causing both superficial and deep infections. *C. glabrata* has several traits that have been linked to virulence, including a repertoire of adhesins, the ability to adapt to and modify the macrophage phagolysosomal environment, and an inherent resistance to azole antifungals ([@bib22]). The organism is genetically tractable, and both transposon mutagenesis and reverse genetic approaches have been used to generate mutants ([@bib21]; [@bib4]; [@bib15]). To expand the range of tools available for *C. glabrata*, we made a panel of expression vectors. The goal was to create a series of *Escherichia coli--C. glabrata* shuttle vectors containing different *C. glabrata* promoters and a choice of yeast-selectable markers. Analogous shuttle vectors have been designed for use in *Saccharomyces cerevisiae* and other yeasts ([@bib23]; [@bib8]; [@bib13]; [@bib20]; [@bib6]; [@bib2]; [@bib1]; [@bib5]).

This series of cloning vectors contains a pMB1 (ColE1 family) origin of replication and Ap^R^ marker for propagation in *E. coli*. A *C. glabrata* CEN sequence and an ARS element permit propagation and stable maintenance of the plasmid. A polylinker positioned between the *C. glabrata*--specific promoter and a transcriptional terminator facilitate cloning of genes of interest under control of a given promoter. We constructed this series of plasmids with a range of *C. glabrata* promoters; there are three constitutively active promoters, two macrophage-induced promoters, and one nutritionally regulated promoter. These options allow researchers to vary the level of expression for a target gene, and because the plasmids use the same polylinker, target genes can be easily shuttled between backbones with different promoters. Additionally, there is a choice of two selectable markers for use in *C. glabrata*, the *URA3* auxotrophic marker or the dominant NAT drug-resistance cassette.

We describe the construction of these plasmids and quantify the expression level driven by each promoter by monitoring GFP expression by flow cytometry or by quantitative reverse-transcription polymerase chain reaction (qRT-PCR). This set of vectors will facilitate regulated or constitutive expression of genes in *C. glabrata* and expands the genetic toolbox available for *C. glabrata*.

Materials and Methods {#s1}
=====================

Growth media {#s2}
------------

*C. glabrata* was routinely grown on YPD media (10 g/liter yeast extract, 20 g/liter peptone, 2% dextrose) at 30°C. All solid media contained 2% agar. Nourseothricin (NAT; clonNAT; Werner BioAgents) was supplemented to liquid YPD media at 50 μg/ml and to solid YPD media at 100 μg/ml to select for *C. glabrata* strains containing pCN vectors. Strains containing *URA3*-marked plasmids (pCU series) were grown in SD-Ura (1.7 g/liter yeast nitrogen base without amino acids or ammonium sulfate, 5 g/liter ammonium sulfate, 6 g/liter casamino acids, 2% dextrose).

The *MET3* promoter is controlled by the presence of methionine and cysteine in the media. Media lacking methionine, cysteine, and uracil was used to induce expression, whereas addition of Met and Cys (2 mM each) was used to repress the *MET3* promoter. SD−Met−Cys−Ura and SD+Met+Cys−Ura media were made using +Met+Cys−Ura or −Met−Cys−Ura amino acid mixtures, respectively. For the pCN-MET3 vectors, SED media (1.7 g/liter yeast nitrogen base without amino acids or ammonium sulfate, 1 g/liter monosodium glutamate, 2% dextrose) is used instead of standard SD, because NAT is not inhibitory in the presence of ammonium sulfate ([@bib7]). The resulting SED−Met−Cys−Ura and SED+Met+Cys−Ura media were supplemented with Nat (50 μg/ml in liquid, 100 μg/ml in plates). [Supporting Information](http://www.g3journal.org/lookup/suppl/doi:10.1534/g3.113.006908/-/DC1/006908SI.pdf), [Table S1](http://www.g3journal.org/lookup/suppl/doi:10.1534/g3.113.006908/-/DC1/TableS1.pdf) shows the components of each amino acid mixture.

Experiments testing plasmid maintenance required counterselection against the *URA3* marker using 5-fluoroorotic acid (5-FOA). For these purposes, colonies were grown on 5-FOA plates (1.7 g/liter yeast nitrogen base without amino acids or ammonium sulfate, 5 g/liter ammonium sulfate, 6 g/liter casamino acids, 25 mg/liter uracil, 1 g/liter 5-FOA, 2% dextrose, 2% agar).

Strains and transformation {#s3}
--------------------------

*E. coli* was grown in LB and transformants were selected in LB plus 100 μg/ml carbenicillin. All *C. glabrata* strains used in this study are listed in [Table 1](#t1){ref-type="table"} ([@bib9]). *C. glabrata* strains were transformed using a modified LiOAc transformation protocol as described previously ([@bib4]). pCU plasmids were transformed into strain BG14 and transformants selected on SD−Ura plates. pCN plasmids were transformed into strain BG2 and transformants were selected in the presence of NAT (100 μg/ml).

###### *C. glabrata* strains used in this study

  Strain                                              Description           Genotype                                  Parent Strain   Source
  --------------------------------------------------- --------------------- ----------------------------------------- --------------- -------------------------
  General use                                                                                                                         
  BG2                                                 Clinical isolate      Wild-type clinical isolate                NA              Cormack and Falkow 1999
  BG14                                                Ura− version of BG2   *ura3*Δ::Tn903 G418^R^                    BG2             Cormack and Falkow 1999
  CBS138                                              Clinical isolate      Wild-type clinical isolate (ATCC\#2001)   NA              ATCC
  BG2389                                              qPCR control          *ura3*Δ::Tn903 G418^R^                    BG14            S. Pan, unpublished
                                                                            *sla2*Δ::Hyg^R^ (*URA3*, Amp^R^)                          
  Constitutive promoters (*URA3*-marked)                                                                                              
  BG3316                                              pCU-EGD2 \#1          *ura3*Δ::Tn903 G418^R^, pCU-EGD2          BG14            This work
  BG3317                                              pCU-EGD2 \#2          *ura3*Δ::Tn903 G418^R^, pCU-EGD2          BG14            This work
  BG2988                                              pCU-EGD2-GFP \#1      *ura3*Δ::Tn903 G418^R^, pCU-EGD2-GFP      BG14            This work
  BG3147                                              pCU-EGD2-GFP \#2      *ura3*Δ::Tn903 G418^R^, pCU-EGD2-GFP      BG14            This work
  BG3318                                              pCU-HHT2 \#1          *ura3*Δ::Tn903 G418^R^, pCU-HHT2          BG14            This work
  BG3319                                              pCU-HHT2 \#2          *ura3*Δ::Tn903 G418^R^, pCU-HHT2          BG14            This work
  BG2989                                              pCU-HHT2-GFP \#1      *ura3*Δ::Tn903 G418^R^, pCU-HHT2-GFP      BG14            This work
  BG3148                                              pCU-HHT2-GFP \#2      *ura3*Δ::Tn903 G418^R^, pCU-HHT2-GFP      BG14            This work
  BG3320                                              pCU-PDC1 \#1          *ura3*Δ::Tn903 G418^R^, pCU-PDC1          BG14            This work
  BG3321                                              pCU-PDC1 \#2          *ura3*Δ::Tn903 G418^R^, pCU-PDC1          BG14            This work
  BG2990                                              pCU-PDC1-GFP \#1      *ura3*Δ::Tn903 G418^R^, pCU-PDC1-GFP      BG14            This work
  BG3149                                              pCU-PDC1-GFP \#2      *ura3*Δ::Tn903 G418^R^, pCU-PDC1-GFP      BG14            This work
  Constitutive promoters (NAT^R^-marked)                                                                                              
  BG3328                                              pCN-EGD2 \#1          pCN-EGD2                                  BG2             This work
  BG3329                                              pCN-EGD2 \#2          pCN-EGD2                                  BG2             This work
  BG3342                                              pCN-EGD2-GFP \#1      pCN-EGD2-GFP                              BG2             This work
  BG3343                                              pCN-EGD2-GFP \#2      pCN-EGD2-GFP                              BG2             This work
  BG3330                                              pCN-HHT2 \#1          pCN-HHT2                                  BG2             This work
  BG3331                                              pCN-HHT2 \#2          pCN-HHT2                                  BG2             This work
  BG3344                                              pCN-HHT2-GFP \#1      pCN-HHT2-GFP                              BG2             This work
  BG3345                                              pCN-HHT2-GFP \#2      pCN-HHT2-GFP                              BG2             This work
  BG3332                                              pCN-PDC1 \#1          pCN-PDC1                                  BG2             This work
  BG3333                                              pCN-PDC1 \#2          pCN-PDC1                                  BG2             This work
  BG3346                                              pCN-PDC1-GFP \#1      pCN-PDC1-GFP                              BG2             This work
  BG3347                                              pCN-PDC1-GFP \#2      pCN-PDC1-GFP                              BG2             This work
  Phagocytosis-induced promoters (*URA3*-marked)                                                                                      
  BG3322                                              pCU-ACO2 \#1          *ura3*Δ::Tn903 G418^R^, pCU-ACO2          BG14            This work
  BG3323                                              pCU-ACO2 \#2          *ura3*Δ::Tn903 G418^R^, pCU-ACO2          BG14            This work
  BG2978                                              pCU-ACO2-GFP \#1      *ura3*Δ::Tn903 G418^R^, pCU-ACO2-GFP      BG14            This work
  BG2979                                              pCU-ACO2-GFP \#2      *ura3*Δ::Tn903 G418^R^, pCU-ACO2-GFP      BG14            This work
  BG3324                                              pCU-LYS21 \#1         *ura3*Δ::Tn903 G418^R^, pCU-LYS21         BG14            This work
  BG3325                                              pCU-LYS21 \#2         *ura3*Δ::Tn903 G418^R^, pCU-LYS21         BG14            This work
  BG2982                                              pCU-LYS21-GFP \#1     *ura3*Δ::Tn903 G418^R^, pCU-LYS21-GFP     BG14            This work
  BG2983                                              pCU-LYS21-GFP \#2     *ura3*Δ::Tn903 G418^R^, pCU-LYS21-GFP     BG14            This work
  Phagocytosis-induced promoters (NAT^R^-marked)                                                                                      
  BG3334                                              pCN-ACO2 \#1          pCN-ACO2                                  BG2             This work
  BG3335                                              pCN-ACO2 \#2          pCN-ACO2                                  BG2             This work
  BG3348                                              pCN-ACO2-GFP \#1      pCN-ACO2-GFP                              BG2             This work
  BG3349                                              pCN-ACO2-GFP \#2      pCN-ACO2-GFP                              BG2             This work
  BG3336                                              pCN-LYS21 \#1         pCN-LYS21                                 BG2             This work
  BG3337                                              pCN-LYS21 \#2         pCN-LYS21                                 BG2             This work
  BG3350                                              pCN-LYS21-GFP \#1     pCN-LYS21-GFP                             BG2             This work
  BG3351                                              pCN-LYS21-GFP \#2     pCN-LYS21-GFP                             BG2             This work
  Nutritionally regulated promoters (*URA3*-marked)                                                                                   
  BG3326                                              pCU-MET3 \#1          *ura3*Δ::Tn903 G418^R^, pCU-MET3          BG14            This work
  BG3327                                              pCU-MET3 \#2          *ura3*Δ::Tn903 G418^R^, pCU-MET3          BG14            This work
  BG2512                                              pCU-MET3-GFP \#1      *ura3*Δ::Tn903 G418^R^, pCU-MET3-GFP      BG14            This work
  BG3340                                              pCU-MET3-GFP \#2      *ura3*Δ::Tn903 G418^R^, pCU-MET3-GFP      BG14            This work
  Nutritionally regulated promoters (NAT^R^-marked)                                                                                   
  BG3338                                              pCN-MET3 \#1          pCN-MET3                                  BG2             This work
  BG3339                                              pCN-MET3 \#2          pCN-MET3                                  BG2             This work
  BG3352                                              pCN-MET3-GFP \#1      pCN-MET3-GFP                              BG2             This work
  BG3353                                              pCN-MET3-GFP \#2      pCN-MET3-GFP                              BG2             This work

NA, not applicable; NAT^R^, nourseothricin-resistant.

Plasmid construction {#s4}
--------------------

All plasmids used in this study are listed in [Table 2](#t2){ref-type="table"}. The *URA3*-marked and NAT-marked plasmid backbones are derived from the pGRB2.1 and pBM16 plasmids, respectively ([@bib12]; [@bib19]). We include a more complete description of their design here.

###### Plasmids used in this study

  Plasmid Name                        Description                                                                                                    Parent Vector   Bacterial Stock   Source                   Genbank Accession   Addgene ID
  ----------------------------------- -------------------------------------------------------------------------------------------------------------- --------------- ----------------- ------------------------ ------------------- ------------
  General use                                                                                                                                                                                                                       
  pGRB2.0                             CEN/ARS plasmid \[Ap^R^, *URA3*\]                                                                              pRS406          b65               G. Rotano, unpublished   KF040394            45340
  pGRB2.1                             CEN/ARS plasmid containing HIS3 3′ UTR \[Ap^R^, *URA3*\]                                                       pGRB2.0         b54               [@bib12]                 KF040395            45341
  pGRB2.2                             PGK1pr on CEN/ARS plasmid also containing HIS3 3′ UTR \[Ap^R^, *URA3*\]                                        pGRB2.1         b162              [@bib12]                 KF040396            45342
  pGRB2.3                             GFP driven by PGK1pr on CEN/ARS plasmid \[Ap^R^, *URA3*\]                                                      pGRB2.2         b164              This work                KF040397            45343
  pBM16                               CEN/ARS plasmid containing NAT^R^ cassette \[Ap^R^, NAT^R^\]                                                   pUC19           b1564             [@bib19]                 KF040398            45344
  pBM16.1                             CEN/ARS plasmid containing NAT^R^ cassette; same backbone as pBM16, with more limited MCS. \[Ap^R^, NAT^R^\]   pBM16           b1879             This work                KF040399            45345
  Constitutive promoters                                                                                                                                                                                                            
  pCU-EGD2                            EGD2pr empty vector \[Ap^R^, *URA3*\]                                                                          pGRB2.1         b2448             This work                KF040370            45315
  pCU-EGD2-GFP                        EGD2pr-GFP \[Ap^R^, *URA3*\]                                                                                   pGRB2.3         b2037             This work                KF040371            45316
  pCN-EGD2                            EGD2pr empty vector \[Ap^R^, NAT^R^\]                                                                          pBM16.1         b2454             This work                KF040372            45317
  pCN-EGD2-GFP                        EGD2pr-GFP \[Ap^R^, NAT^R^ \]                                                                                  pBM16           b2236             This work                KF040373            45318
  pCU-HHT2                            HHT2pr empty vector \[Ap^R^, *URA3*\]                                                                          pGRB2.1         b2449             This work                KF040374            45319
  pCU-HHT2-GFP                        HHT2pr-GFP \[Ap^R^, *URA3*\]                                                                                   pGRB2.3         b2038             This work                KF040375            45320
  pCN-HHT2                            HHT2pr empty vector \[Ap^R^, NAT^R^\]                                                                          pBM16.1         b2455             This work                KF040376            45321
  pCN-HHT2-GFP                        HHT2pr-GFP \[Ap^R^, NAT^R^\]                                                                                   pBM16           b2238             This work                KF040377            45322
  pCU-PDC1                            PDC1pr empty vector \[Ap^R^, *URA3*\]                                                                          pGRB2.1         b2450             This work                KF040378            45323
  pCU-PDC1-GFP                        PDC1pr-GFP \[Ap^R^, *URA3*\]                                                                                   pGRB2.3         b2039             This work                KF040379            45324
  pCN-PDC1                            PDC1pr empty vector \[Ap^R^, NAT^R^\]                                                                          pBM16.1         b2456             This work                KF040380            45325
  pCN-PDC1-GFP                        PDC1pr-GFP \[Ap^R^, NAT^R^\]                                                                                   pBM16           b2240             This work                KF040381            45326
  Macrophage-induced promoters                                                                                                                                                                                                      
  pCU-ACO2                            ACO2pr empty vector \[Ap^R^, *URA3*\]                                                                          pGRB2.1         b2451             This work                KF040382            45327
  pCU-ACO2-GFP                        ACO2pr-GFP \[Ap^R^, *URA3*\]                                                                                   pGRB2.3         b2230             This work                KF040383            45328
  pCN-ACO2                            ACO2pr empty vector \[Ap^R^, NAT^R^\]                                                                          pBM16.1         b2457             This work                KF040384            45329
  pCN-ACO2-GFP                        ACO2pr-GFP \[Ap^R^, NAT^R^\]                                                                                   pBM16           b2235             This work                KF040385            45330
  pCU-LYS21                           LYS21pr empty vector \[Ap^R^, *URA3*\]                                                                         pGRB2.1         b2452             This work                KF040386            45331
  pCU-LYS21-GFP                       LYS21pr-GFP \[Ap^R^, *URA3*\]                                                                                  pGRB2.3         b2232             This work                KF040387            45332
  pCN-LYS21                           LYS21pr empty vector \[Ap^R^, NAT^R^\]                                                                         pBM16.1         b2458             This work                KF040388            45334
  pCN-LYS21-GFP                       LYS21pr-GFP \[Ap^R^, NAT^R^\]                                                                                  pBM16           b2239             This work                KF040389            45335
  Nutritionally regulated promoters                                                                                                                                                                                                 
  pCU-MET3                            MET3pr empty vector \[Ap^R^, *URA3*\]                                                                          pGRB2.1         b2453             This work                KF040390            45336
  pCU-MET3-GFP                        MET3pr-GFP \[Ap^R^, *URA3*\]                                                                                   pGRB2.3         b1971             This work                KF040391            45337
  pCN-MET3                            MET3pr empty vector \[Ap^R^, NAT^R^\]                                                                          pBM16.1         b2459             This work                KF040392            45338
  pCN-MET3-GFP                        MET3pr-GFP \[Ap^R^, NAT^R^\]                                                                                   pBM16           b2410             This work                KF040393            45339

UTR, untranslated region; NAT^R^, nourseothricin-resistant.

The pGRB vectors were created by cloning a chimeric *C. glabrata* CEN/ARS sequence into pRS406 ([@bib23]), which was linearized via *Aat*II restriction digestion, creating pGRB2.0. The CEN sequence was isolated from *C. glabrata* strain BG2 centromere H, based on previously identified *C. glabrata* centromeric sequences ([@bib17]). The ARS sequence was functionally isolated from *C. glabrata* strain BG2 and corresponds to nucleotides 286060-286210 of chromosome F in the published *C. glabrata* CBS138 sequence. The *HIS3* 3′ untranslated region was amplified from *C. glabrata* strain BG2 using polymerase chain reaction (PCR) and cloned into pGRB2.0 as a *Xho*I-*Kpn*I fragment, creating pGRB2.1. The *S. cerevisiae PGK1* promoter was amplified from *S. cerevisiae* using PCR and cloned into pGRB2.1 as a *Sac*I-*Xba*I fragment, creating pGRB2.2 ([@bib11]). The plasmid pGRB2.3 contains yEGFP3 ([@bib10]) downstream of the *PGK1* promoter, cloned as a *Eco*RI and *Sal*I fragment.

The basic NAT^R^ backbone for use in *C. glabrata* is pBM16 ([@bib19]). The NAT^R^ cassette was generated by PCR-amplifying Sc*TEF1*p and the *NAT1* open reading frame and subcloning them into pRS416 ([@bib23]); the resulting Sc*TEF1*p--*NAT1*--*ScCYC1 3′UTR* cassette was isolated as a *Sac*I/*Kpn*I fragment, blunt-ended, and subcloned into the *Nde*I site in the pUC19 backbone, which itself had been blunt-ended. The *C. glabrata* CEN/ARS sequence was PCR-amplified from pGRB2.0 using primers that contained *Aat*II restriction sites and then subcloned into the unique *Aat*II site in the pUC19 backbone, thus creating pBM16. pBM16.1 is the same as pBM16, except its multiple cloning site (MCS) was replaced with an oligonucleotide containing *Sac*I and *Kpn*I sites, to facilitate cloning of *Sac*I/*Kpn*I fragments from pGRB2.0-derived vectors

Primers used to amplify each *C. glabrata* promoter during plasmid construction are listed in [Table 3](#t3){ref-type="table"}. They contain restriction sites to facilitate cloning; all forward primers contain a *Sac*I site and reverse primers contain *Spe*I (for *LYS21*pr) or *Xba*I sites (all others). The *MET3* promoter was amplified from BG2 genomic DNA; all other promoters were amplified from CBS138 genomic DNA. The PCR products were TOPO-cloned (Invitrogen) and sequenced. Empty CEN/ARS *URA3*-marked vectors (pCU series; [Figure 1A](#fig1){ref-type="fig"}) were created by subcloning each promoter using *Sac*I/*Spe*I (for *LYS21*) or *Sac*I/*Xba*I (all others) and ligating them into pGRB2.1 cut with *Sac*I/*Xba*I. The *LYS21* promoter contains an internal *Xba*I site, so *Spe*I was used for subcloning; this eliminates *Xba*I from the MCS of the *LYS21* vectors. The NAT-marked versions of the empty vectors (pCN series; [Figure 1](#fig1){ref-type="fig"}) were created by cloning each pCU series plasmid with *Sac*I/*Kpn*I to release the promoter-MCS-terminator fragment and ligating this into pBM16.1. These NAT-marked empty vectors are the pCN series of plasmids ([Figure 1B](#fig1){ref-type="fig"}). pCU-ACO2 was subcloned to the pBM16.1 vector using a *Sac*I/partial *Kpn*I digestion, because the *ACO2* promoter contains a *Kpn*I site.

###### Primers used in this study

  Oligo Number                        Description       Sequence (5′-\>3′)
  ----------------------------------- ----------------- ----------------------------------------------
  NAT^R^ cassette                                       
  2540                                ScTEF1p, for      caaggagctcCATAGCTTCAAAATGTTTCTACTCC
  2541                                ScTEF1p, rev      cgcggatccAAAACTTAGATTAGATTGCTATGC
  2542                                NAT1 orf, for     ctagagatctAAAATGGGCACCACTCTTGACG
  2543                                NAT1 orf, rev     acgcgtcgacTTAGGGGCAGGGCATGCTCATG
  pBM16.1 MCS                                           
                                      MCS, for          aattgagagctcgaccatcaagggtaccttgca
                                      MCS, rev          aggtacccttgatggtcgagctctc
  Constitutive promoters                                
  4634                                *EGD2*p, for      aaaagagctcTGTCCACTTCACTCACCAGT
  4636                                *EGD2*p, rev      aaaatctagaCTTTGTATATCTGTATTATTG
  4637                                *HHT2*p, for      aaaagagctcTGTTATTGATTATTTATTTATTTG
  4638                                *HHT2*p, rev      aaaatctagaTATGTATGTGTTGTGTTTTG
  4639                                *PDC1*p, for      aaaagagctcAGCATTTTTATACACGTTTTAC
  4640                                *PDC1*p, rev      aaaatctagaTGTTAATGTTTTTTGGCAATTG
  Macrophage-induced promoters                          
  5114                                *ACO2*p, for      attagagctcCTGCAGTGTCCCGTTTGTTTC
  5115                                *ACO2*p, rev      attatctagaTGCTAGTGGGTACGAATTGTAG
  5120                                *LYS21*p, for     attagagctcAGAAAGCGAAGAAGATATATC
  5121                                *LYS21*p, rev     attaactagtCTTTAATATTCTTTGTTCAGC
  Nutritionally regulated promoters                     
  4036                                *MET3*p, for      cttgagagctcATACCAGTTACAATTAGTATTACAATGGTTTAC
  4035                                *MET3*p, rev      gctctagaTTGTTAGGTGTTTCTTTTCTGGAGTGTTA
  qRT-PCR primers                                       
  5980                                GFP, for          CCACTCAATCTGCCTTATC
  5981                                GFP, rev          ATCCATACCATGGGTAATAC
  5883                                *TUB1*, for       GGTGATGTGGTAACAAGAGATG
  5884                                *TUB1*, rev       GTAGCAGATACCGATCTTGAAAC
  6426                                *TUB1*, rev 2     TCGTAGCAGATACCGATCTTGAA
  6597                                Ap^R^ gene, for   AAGCCATACCAAACGACGAG
  6598                                Ap^R^ gene, rev   TTGCCGGGAAGCTAGAGTAA

The DNA sequences of primers used in this article are listed. Capital letters in the DNA sequence hybridize to the target sequence; linkers and restrictions sites added are written in lowercase letters. NAT^R^, nourseothricin-resistant; for, forward; rev, reverse; qRT-PCR, quanitative reverse-transcription polymerase chain reaction.

![Schematic diagrams of the pCU and pCN series of *C. glabrata* vectors. Naming convention was chosen to indicate the plasmids have a CEN/ARS and either *URA3* (pCU; A) or nourseothricin resistance (NAT^R^) (pCN; B) cassettes for selection in *C. glabrata*. Both backbones carry an Ap^R^ gene and pMB1 (ColEI family) origin (not shown) for growth and selection in *E. coli*. The restriction sites in the multiple cloning site (MCS) between the promoter and terminator are listed. \*The *Xba*I site is not present in the MCS of pCU-LYS21 or pCN-LYS21. Refer to [Table 4](#t4){ref-type="table"} to determine which MCS restriction sites are unique in each plasmid, because this depends on the particular backbone and promoter combination. XXX\# is a placeholder to designate the name of the promoter present in a particular vector. (C) The lengths of the promoters cloned into the pCU and pCN vectors using *Sac*I-*Xba*I restriction digestion for all constructs except *LYS21*, which used *Sac*I-*Spe*I, thereby eliminating the *Xba*I site in the MCS, are depicted.](1675f1){#fig1}

Each promoter also was subcloned into pGRB2.3 using *Sac*I/*Xba*I or *Sac*I/*Spe*I restriction digestions, positioning the promoter upstream of the MCS and GFP open reading frame, creating a GFP reporter plasmid. To construct NAT-marked versions of the GFP reporter strains, the promoter-MCS-GFP-terminator fragment was cut from the pGRB backbone using *Sac*I/*Acc*65I restriction digestions and ligated into pBM16. pBM16 has *E. coli* origin of replication and selectable markers, a *C. glabrata* CEN/ARS, and a NAT resistance (NAT^R^) cassette.

All plasmids have been deposited with corresponding sequences at Addgene. Addgene and GenBank accession numbers are included in [Table 2](#t2){ref-type="table"}.

Plasmid copy number {#s5}
-------------------

Total DNA was isolated from *C. glabrata* strains carrying pCU or pCN series plasmids. Log-phase cultures of *C. glabrata* strains were pelleted by centrifugation and washed in a solution of 50 mM Tris (pH 8.0), 10 mM EDTA, and 50 mM β-mercaptoethanol. The cells were resuspended in spheroplasting buffer \[1.1 M sorbitol, 50 mM Tris (pH 8.0), 10 mM EDTA\] supplemented with 1 mM β-mercaptoethanol. Yeast lytic enzyme (\#152270; ICN Biomedicals) was added and the cells were incubated at 30°C for 10 min. Spheroplasts were collected by centrifugation and washed twice in spheroplasting buffer. DNA was isolated from the washed spheroplasts using the MasterPure Yeast DNA Purification Kit (\#MPY80200; Epicentre). Total DNA was treated with RNase and cleaned by phenol/chloroform extraction and ethanol precipitation. Total DNA was then used in a quantitative PCR (qPCR) reaction to assess relative amounts of plasmid and genomic DNA. Plasmid DNA was monitored by amplifying a portion of the Ap^R^ gene (primers 6596 and 6598); genomic DNA was monitored by amplifying a portion of the *TUB1* gene (primers 5883 and 6426) ([Table 3](#t3){ref-type="table"} shows primer sequences). Average cycle threshold values for experimental samples were compared with a standard curve of genomic DNA from strain BG2389 to generate relative starting quantities of DNA. Strain BG2389 has a single copy of the Ap^R^ gene integrated into the genome and is expected to have Ap^R^ and *TUB1* in equal copy number. Quantitative PCR was performed in technical triplicate on each sample with each primer set. The average Ap^R^ and *TUB1* signal was calculated for each strain, and plasmid copy number was calculated as Ap^R^/*TUB1*. Two independent yeast strains carrying a given plasmid were monitored; the plasmid copy number in replicate strains was averaged as shown in [Table S2](http://www.g3journal.org/lookup/suppl/doi:10.1534/g3.113.006908/-/DC1/TableS2.pdf).

Rate of plasmid loss {#s6}
--------------------

Yeast strains were grown to mid-log phase under selection in SD-Ura or YPD+NAT media for pCU or pCN plasmids, respectively. Cultures were washed twice in sterile water and diluted to an optical density (OD) of OD~600~ = 0.02 in YPD (nonselective) media (t = 0) and grown at 30°C. After 5 hr, an OD~600~ measurement was taken to calculate the number of times the culture had doubled, and then culture was diluted back to OD~600~ = 0.02 to keep it in log phase at 30°C. At t = 10 hr, the OD~600~ of the culture was again measured and cells were plated onto YPD (3 plates/media/strain) at approximately 200 cells/plate. Plates were grown at 30°C for 1--2 days and then were replica-plated onto selective media (SD−Ura or YPD+NAT). After 1 day of growth at 30°C, the selective plates were scored for colonies having lost the plasmid (Ura^-^ or NAT^S^) or having retained the plasmid (any portion of the colony is Ura^+^ or NAT^R^). At each time point, the fraction of the population that contained the plasmid on the original YPD plates was calculated from the selective plates as CFU~growth~/CFU~total~. The number of generations between time points was the sum of the number of generations from t = 0 to t = 5, and then from t = 5 to t = 10, using the formula \[\#gen = log~2~(OD~t2~/OD~t1~)\]. The rate of plasmid loss per generation was calculated as:$$\begin{array}{l}
{1\text{-}\left\{ \left\lbrack {\left( {\left. \text{fraction\ of\ the\ population\ with\ plasmid\ at\ t} = 10h \right)/\left( \text{fraction\ of\ population\ with\ plasmid\ at\ t} = 0h \right)} \right\rbrack\hat{}\left( 1/\left. \text{generations} \right) \right\}.} \right. \right.} \\
\end{array}$$

Plasmid integration into genome {#s7}
-------------------------------

Two *C. glabrata* yeast strains carrying pCU-PDC1 were grown to saturation in liquid SD−Ura media. Cultures were plated onto 10 SD−Ura plates each, at a density of approximately 100 colonies per plate and grown 2 days at 30°C. These colonies were then replica-plated onto 5-FOA media and grown overnight at 30°C. Each colony on the original SD−Ura plate was monitored to determine if it was sensitive or resistant to 5-FOA. If the pCU-PDC1 plasmid had integrated into the genome, we would have anticipated a 5-FOA^S^ phenotype ([@bib4]), whereas cells in which the pCU plasmid is maintained as an episome show a 5-FOA^R^ phenotype, reflecting plasmid loss.

Flow cytometry {#s8}
--------------

Cells from liquid cultures were washed twice in sterile PBS and resuspended in 0.5 ml PBS. A FACScalibur flow cytometer (BD Biosciences) was used to measure GFP fluorescence. Detector levels were adjusted such that a nonfluorescent strain had a median fluorescence of approximately 10. Populations also were gated based on forward and side scatter of the nonfluorescent strain. For each sample, data for 10^4^ gated cells were collected using CellQuest Pro software (BD Biosciences). Further statistical analysis and graphical representation were performed using FloJo software. Fluorescence was measured from two independent strains carrying each construct. "Stationary" samples were taken from cultures grown overnight in appropriate media. The overnight cultures were diluted 1:20 and grown at 30°C for 4 hr, to OD~600~ of approximately 0.3, and used as the "exponential" samples.

Phagocytosis assays and *C. glabrata* isolation {#s9}
-----------------------------------------------

Phagocytosis assays were performed as previously described, with some alterations ([@bib16]). Murine macrophage-like cell line J774A.1 cells were seeded into 15-cm-diameter tissue culture (TC) dishes (BD353025; BD Bioscience) and grown to confluence in DMEM plus fetal bovine serum (FBS) plus P/S (DMEM supplemented with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin; 120-095-72; Quality Biologicals). Log-phase *C. glabrata* cells were added to the J477A.1 cells at a multiplicity of infection of 3 and incubated at 37°C plus 5% CO~2~ for 1 hr to allow the yeast to settle onto the J477A.1 cells. After incubating for 1 hr, the non-cell-associated yeast were removed by aspiration and washing in DMEM. The J477A.1 and *C. glabrata* were coincubated for an additional 2 hr. After 2 hr, media was decanted and the macrophages were scraped from the TC dishes and lysed in 10 ml cold DEPC dH~2~O supplemented with RNaseA (Fermentas EN0531) and RNaseA/T1 (Fermentas EN0551) to digest mammalian RNA. *C. glabrata* released from the J774A.1 cells were collected by centrifugation (4000 rpm, 4°C, 10 min). The *C. glabrata* cells were then washed twice in cold DEPC dH~2~O containing RNase inhibitors (Protect RNA, Sigma R7397) and spun as described previously. Finally, the *C. glabrata* cells were resuspended in 1 ml DEPC dH~2~O plus Protect RNA and transferred to 2-ml screw-cap tubes that contained approximately 500 μl acid-washed glass beads. The cells were spun in a microfuge (4000 rpm, 4°C, 5 min). The supernatant accessible above the glass beads was aspirated and the yeast were frozen in liquid nitrogen and stored at −80°C until RNA isolation commenced.

To control for growth in DMEM and TC conditions, *C. glabrata* cells also were inoculated into TC dishes with DMEM supplemented with FBS and P/S without J774A.1 and grown for a total of 3 hr at 37°C plus 5% CO~2~. The contents of the dish were transferred to a 50-ml conical tube and centrifuged (4000 rpm, 4°C, 10 min). The pelleted yeast were washed in DEPC dH~2~O supplemented with Protect RNA, transferred to a screw-cap tube, and pelleted with glass beads as described.

Quantitative reverse-transcription PCR to monitor promoter strength {#s10}
-------------------------------------------------------------------

RNA was isolated from *C. glabrata* (phagocytosed or media-grown controls) using a guanidine thiocyanate mixture (4 M guanidine thiocyanate, 2% β-ME) lysis and acid phenol extraction; 0.4 ml guanidine thiocyanate mixture was added to each frozen pellet and cells were disrupted using a Fast-Prep (Bio101 Thermo Savant). Lysates were transferred to a new nuclease-free tube and RNA was recovered by performing two acid phenol/chloroform extractions. The extracted RNA was then precipitated and resuspended in DEPC dH~2~O. The RNA was treated with DNase (NEB B0303S) to remove any residual genomic DNA, and then the acid phenol extraction and ethanol precipitation were performed again. Reverse-transcription of purified RNA was performed linearly with Superscript III (Invitrogen). Quantitative PCR was performed in triplicate, monitoring EvaGreen fluorescence in a BioRad Thermocycler. Relative GFP expression for each strain is calculated as the average GFP signal normalized to the average *TUB1* values (primers 5883 and 5884). [Figure 4](#fig4){ref-type="fig"} shows the relative expression for each strain, averaged across two biological replicates of the macrophage infection.

Phagocytosis assays and microscopic imaging {#s11}
-------------------------------------------

*C. glabrata* strains carrying pCU-ACO2-GFP or pCU-LYS21-GFP plasmids were grown to OD of 7.8--9.4 in SD-Ura media. The cells were washed in PBS and resuspended at a density of 4×10\^6 cells/ml in DMEM supplemented with FBS and P/S. J774A.1 cells were seeded into 24-well tissue culture plates (Beckman Dickinson 353047) with or without sterile glass coverslips in each well. Once the J774A.1 had grown to confluence, they were washed with fresh DMEM, which was then aspirated from the wells. Each well was then filled with 100 μl yeast cells in DMEM supplemented with FBS and P/S, which is effectively a multiplicity of infection of 1 (estimating 4×10^5^ macrophages/well). After a 1-hr incubation at 37°C plus 5% CO~2~, during which the yeast settled onto the macrophage and were engulfed, the media and unbound yeast were aspirated from the wells. The J774A.1 cells were washed twice with DMEM to remove any unbound yeast and 500 μl DMEM supplemented with FBS and P/S was added to each well. The yeast and J774A.1 cells were coincubated for an additional 2 hr. To stop the infection, the media was aspirated from the wells with coverslips and the J774A.1 and *C. glabrata* were fixed in a 1% formaldehyde solution for 5 min. The coverslips were then washed in PBS and then mounted onto glass slides with Vectashield. In parallel, 100 μl yeast cells were seeded into 24-well plates without J774A.1 cells to control for growth conditions and were allowed to grow for a total of 3 hr. These yeast were pelleted in microfuge tubes, media was aspirated, and the cells were resuspended and fixed in 1% formaldehyde solution for 5 min. The fixed unphagocytosed yeast were mounted onto glass slides without Vectashield. All samples were imaged on a Zeiss Axioskop microscope at 100× objective and bright field differential image contrast and fluorescent images were captured.

Results {#s12}
=======

Plasmid design and construction {#s13}
-------------------------------

The plasmids described here were designed as tools for molecular genetic experiments in *C. glabrata*. Promoters of six genes were chosen and cloned into *URA3*-marked or NAT^R^-marked episomal plasmids. In addition to making "empty" vectors suitable for cloning any desired gene under the control of each promoter, reporter constructs were created where GFP was cloned into each set of plasmids so that the relative strength of each promoter could be measured by monitoring GFP abundance.

Three "constitutive" promoters were chosen from unpublished data analyzing transcriptional profiles of *C. glabrata* cells growing in YPD in exponential phase or stationary phase. These promoters, *EGD2* (CAGL0M07161g), *HHT2* (CAGL0C04114g), and *PDC1* (CAGL0M07920g), were chosen as representatives of low-level, medium-level, and high-level expression during both exponential phase and stationary phase growth. Using transcriptional microarray data comparing *C. glabrata* expression in RPMI and after phagocytosis by the macrophage-like mammalian cell line J774A.1 ([@bib16]), we identified promoters with a high macrophage/RPMI ratio. To identify genes specifically induced after phagocytosis, rather than by starvation, we selected genes that were not strongly induced in the stationary phase, as compared with the exponential phase, when grown in laboratory media (B. Green, unpublished data). From this analysis, we chose *ACO2* (CAGL0F02431g) and *LYS21* (CAGL0J09240g) as phagocytosis-induced genes. Finally, the *MET3* (CAGL0B03839g) promoter was developed as a regulatable promoter based on similar constructs used in *S. cerevisiae* and *Candida albicans* ([@bib24]; [@bib3]).

For most genes, we used PCR amplification to isolate and clone the promoter (the complete intergenic region upstream of the designated gene). For the *MET3* promoter, we amplified 1026 bp immediately upstream of the *MET3* open reading frame. The length of each cloned promoter is indicated in [Figure 1C](#fig1){ref-type="fig"}.

Ultimately, each promoter was cloned into four plasmid backbones for use in *C. glabrata*. The backbones contain a *URA3* auxotrophic marker or a dominant NAT^R^ cassette, as well as a multiple cloning site or GFP downstream of the promoters. Plasmids containing the *C. glabrata* CEN/ARS and the *URA3* auxotrophic marker are designated as the pCU series ([Figure 1A](#fig1){ref-type="fig"}). They are derived from the pGRB plasmid backbone, which contains a *S. cerevisiae URA3* cassette to serve as an auxotrophic marker and functions for selection in *C. glabrata*. The pCU plasmids also contain an Ap^R^ gene and F1, M13, and pMB1 (ColE1 family) origins for growth and selection in *E. coli*. The pCN series of plasmids have the *C. glabrata* CEN/ARS and a NAT^R^ cassette for selection and maintenance in *C. glabrata* ([Figure 1B](#fig1){ref-type="fig"}). The pCN plasmids are derived from pBM16.1, which has an Ap^R^ gene and a pMB1 (ColE1 family) origin for growth and selection in *E. coli*. Plasmid names and descriptions are indicated in [Table 3](#t3){ref-type="table"}.

The "empty" versions of each pCU and pCN series plasmid contain an MCS immediately downstream of the promoter, followed by a *HIS3* terminator. These vectors are suitable for further subcloning, placing any gene of interest under the control of the given promoter. [Table 4](#t4){ref-type="table"} lists the restriction enzyme recognition sites found in the MCS for each plasmid and indicates which sites are unique for each construct. Additionally, we made versions of each plasmid that have GFP placed under the control of each promoter. These reporter plasmids were used to assess the strength of each promoter through monitoring GFP expression levels.

###### Restriction sites found in the multiple cloning sites of the pCU and pCN plasmids

               Promoter     MCS          Other Sites                                                                                                                                        
  ------------ ------------ ------------ ------------- ------------- ------------ ------------- ------------- ------------- ----------- ------------ ------------ ------------ ------------ ------------
  pCU series   *EGD2*       ***Xba*I**   ***Spe*I**    ***Bam*HI**   ***Sma*I**   *Pst*I        ***Eco*RI**   *Eco*RV       *Hind*III   *Cla*I       *Sal*I       ***Xho*I**   ***Sac*I**   ***Kpn*I**
  *HHT2*       ***Xba*I**   ***Spe*I**   ***Bam*HI**   ***Sma*I**    *Pst*I       *Eco*RI       *Eco*RV       *Hind*III     *Cla*I      *Sal*I       ***Xho*I**   ***Sac*I**   ***Kpn*I**   
  *PDC1*       ***Xba*I**   ***Spe*I**   *Bam*HI       ***Sma*I**    *Pst*I       ***Eco*RI**   *Eco*RV       *Hind*III     *Cla*I      ***Sal*I**   ***Xho*I**   ***Sac*I**   ***Kpn*I**   
  *ACO2*       ***Xba*I**   *Spe*I       *Bam*HI       ***Sma*I**    *Pst*I       *Eco*RI       *Eco*RV       *Hind*III     *Cla*I      ***Sal*I**   *Xho*I       ***Sac*I**   *Kpn*I       
  *LYS21*                   ***Spe*I**   *Bam*HI       ***Sma*I**    *Pst*I       ***Eco*RI**   *Eco*RV       *Hind*III     *Cla*I      *Sal*I       ***Xho*I**   ***Sac*I**   ***Kpn*I**   
  *MET3*       ***Xba*I**   ***Spe*I**   *Bam*HI       ***Sma*I**    *Pst*I       ***Eco*RI**   *Eco*RV       *Hind*III     *Cla*I      ***Sal*I**   ***Xho*I**   ***Sac*I**   ***Kpn*I**   
  pCN series   *EGD2*       ***Xba*I**   ***Spe*I**    ***Bam*HI**   *Sma*I       ***Pst*I**    ***Eco*RI**   ***Eco*RV**   *Hind*III   *Cla*I       *Sal*I       ***Xho*I**   ***Sac*I**   ***Kpn*I**
  *HHT2*       ***Xba*I**   ***Spe*I**   ***Bam*HI**   *Sma*I        *Pst*I       *Eco*RI       ***Eco*RV**   *Hind*III     *Cla*I      *Sal*I       ***Xho*I**   ***Sac*I**   ***Kpn*I**   
  *PDC1*       ***Xba*I**   ***Spe*I**   *Bam*HI       *Sma*I        *Pst*I       ***Eco*RI**   ***Eco*RV**   *Hind*III     *Cla*I      ***Sal*I**   ***Xho*I**   ***Sac*I**   ***Kpn*I**   
  *ACO2*       ***Xba*I**   *Spe*I       *Bam*HI       *Sma*I        *Pst*I       *Eco*RI       *Eco*RV       *Hind*III     *Cla*I      ***Sal*I**   *Xho*I       ***Sac*I**   *Kpn*I       
  *LYS21*                   ***Spe*I**   *Bam*HI       *Sma*I        ***Pst*I**   ***Eco*RI**   ***Eco*RV**   *Hind*III     *Cla*I      *Sal*I       ***Xho*I**   ***Sac*I**   ***Kpn*I**   
  *MET3*       ***Xba*I**   ***Spe*I**   *Bam*HI       *Sma*I        *Pst*I       ***Eco*RI**   ***Eco*RV**   *Hind*III     *Cla*I      ***Sal*I**   ***Xho*I**   ***Sac*I**   ***Kpn*I**   

Bold lettering indicates the sequence is unique in that particular plasmid. Sites listed under the MCS heading are found in the multiple cloning site of the plasmid; *Sac*I and *Kpn*I are located at the beginning of the promoter and end of the *HIS3* terminator, respectively. MCS, multiple cloning site.

Plasmid maintenance {#s14}
-------------------

Three aspects of these plasmids were monitored to characterize plasmid maintenance in *C. glabrata*: the copy number, the rate of plasmid loss, and the rate at which the plasmids integrate into the genome. Copy number was measured using qPCR to amplify the Ap^R^ gene (from the plasmid backbone) and *TUB1* (from the genome) from total DNA isolated from select yeast strains. *C. glabrata* strains carrying pCU-EGD2, pCN-EGD2, pCU-ACO2, or pCN-ACO2 were chosen because these constructs contain the shortest (*EGD2*) and longest (*ACO2*) promoters in both backbones. As shown in [Table S2](http://www.g3journal.org/lookup/suppl/doi:10.1534/g3.113.006908/-/DC1/TableS2.pdf), the pCU vectors are present at approximately 2 copies per cell. The pCN vectors are present at 0.6 to 0.8 copies per cell.

Plasmid stability was measured by growing four *C. glabrata* strains carrying pCU-PDC1 or pCN-PDC1 (2 strains per construct) nonselectively for 10 hr and determining how many cells retain the plasmid by plating on selective media. We estimate pCU-PDC1 plasmids were lost at a rate of 4.6% per generation, and pCN-PDC1 plasmids were lost at a rate of 6.55% per generation ([Table S3](http://www.g3journal.org/lookup/suppl/doi:10.1534/g3.113.006908/-/DC1/TableS3.pdf)).

Finally, we wanted to ensure that the pCU and pCN plasmids do not integrate into the genome. Two *C. glabrata* strains carrying pCU-PDC1 were grown selectively in SD−Ura media to saturation and then plated to SD−Ura. The SD−Ura plates were replica-plated to plates containing 5-FOA to counterselect any colonies that contained the *URA3* gene. Any 5-FOA^S^ colonies would represent cells that had integrated the *URA3* gene (and presumably the entire plasmid) into the genome. Conversely, 5-FOA^R^ cells represent those with *URA3* on an episomal plasmid, which may be lost and permit growth on 5-FOA. No 5-FOA^S^ colonies were detected in either strain tested, suggesting rates of integration into the genome are \<0.04% ([Table S4](http://www.g3journal.org/lookup/suppl/doi:10.1534/g3.113.006908/-/DC1/TableS4.pdf)).

Expression from *C. glabrata* promoters {#s15}
---------------------------------------

The relative strength of each promoter was analyzed by monitoring GFP expression in *C. glabrata* strains carrying each plasmid construct. Fluorescence in strains carrying the pCU series of plasmids growing exponentially in SD−Ura was measured by flow cytometry ([Figure 2](#fig2){ref-type="fig"}). For each promoter construct, two *C. glabrata* strains carrying the empty vector and two strains carrying the GFP reporter plasmid were tested. Comparing the median fluorescence for the populations in [Figure 2, A--C](#fig2){ref-type="fig"}, the flow cytometry indicates expression from the pCU-EGD2-GFP is the lowest (median ∼30), followed by *HHT2* (median ∼89), and strains carrying pCU-PDC1-GFP had the highest level of fluorescence (median ∼202). This relationship of increasing strength of promoters (*EGD2*\<*HHT2*\<*PDC1*) is also true in stationary cultures, but expression from all strains is lower than what is observed in the corresponding log-phase cultures ([Figure 3](#fig3){ref-type="fig"}). In [Figure 2](#fig2){ref-type="fig"}, the histograms for strains carrying pCU-HHT2-GFP and pCU-PDC1-GFP have shoulders, possibly reflecting cells that have lost the plasmid or alternatively were delayed in exiting stationary phase.

![Fluorescence of exponential phase *C. glabrata* strains carrying pCU series plasmids. Flow cytometry was used to measure fluorescence levels in *C. glabrata* strains carrying pCU series plasmids containing *EGD2* (A), *HHT2* (B), *PDC1* (C), *ACO2* (D), and *LYS21* (E) promoters. The strains were diluted from a saturated overnight culture and grown to OD~600~ of approximately 0.3 before fluorescence was measured. Each panel depicts histograms of fluorescence for two *C. glabrata* strains containing the empty vectors (red and blue lines) and two *C. glabrata* strains containing GFP reporter vectors (green and orange lines) for a given promoter. The median fluorescence value for each strain population is shown.](1675f2){#fig2}

![Fluorescence of stationary phase *C. glabrata* strains carrying pCU series plasmids. Flow cytometry was used to measure fluorescence levels in *C. glabrata* strains carrying pCU series plasmids containing *EGD2* (A), *HHT2* (B), *PDC1* (C), *ACO2* (D), and *LYS21* (E) promoters. Fluorescence of saturated overnight cultures was measured. Each panel depicts histograms of fluorescence for two *C. glabrata* strains containing the empty vectors (red and blue lines) and two *C. glabrata* strains containing GFP reporter vectors (green and orange lines) for a given promoter. The median fluorescence value for each strain population is shown.](1675f3){#fig3}

The expression driven by the *ACO2* and *LYS21* phagocytosis-induced promoters also was assessed in standard laboratory media to assess the basal levels of expression from the *ACO2* and *LYS21* promoters during laboratory culture. To this end, *C. glabrata* strains carrying the pCU-ACO2-GFP and pCU-LYS21-GFP plasmids were grown in SD−Ura media and fluorescence was assessed using flow cytometry ([Figure 2, D and E](#fig2){ref-type="fig"}). As seen in [Figure 2D](#fig2){ref-type="fig"}, the *ACO2* promoter has extremely low basal expression in exponentially growing *C. glabrata* cells in SD−Ura media. The *LYS21* promoter has low basal expression in laboratory media, on par with the levels seen using the constitutive promoter *EGD2* ([Figure 2, E and A](#fig2){ref-type="fig"}).

Similar results were seen for *C. glabrata* strains carrying the pCN series of plasmids when grown in YPD+NAT media (data not shown).

Expression after phagocytosis {#s16}
-----------------------------

The *C. glabrata* strains carrying plasmids with the phagocytosis-induced *ACO2* and *LYS21* promoters were used to infect J774A.1 cells and expression from the promoters was assessed by measuring GFP transcript levels using qRT-PCR. *C. glabrata* cells were isolated from J774A.1 cells after 2 hr of infection and GFP expression was measured (as normalized to *TUB1*). To control for growth in tissue culture media and conditions, *C. glabrata* also were grown in DMEM supplemented with FBS and P/S for an equivalent amount of time and GFP expression was monitored. As seen in [Figure 4](#fig4){ref-type="fig"}, expression of GFP from the pCU-ACO2-GFP or pCU-LYS21-GFP plasmids increased markedly in *C. glabrata* strains that had been phagocytosed by J774A.1 macrophage-like cells. Increased GFP expression also can be observed by fluorescence microscopy of phagocytosed *C. glabrata* cells ([Figure 5](#fig5){ref-type="fig"}).

![Quantitative reverse-transcription PCR (qRT-PCR) results of GFP expression during phagocytosis. qRT-PCR assessment of relative expression of *GFP* (normalized to *TUB1*) in *C. glabrata* grown in media or after phagocytosis by J774A.1 macrophage-like cells. The data are averages of two biological replicates (qPCR performed in triplicate) for each strain; error bars indicate the SD between the averages. The numbers above the bars indicate the average fold-change in *GFP* expression (normalized to *TUB1*) in *C. glabrata* that have been phagocytosed by J774A.1 (macrophage) *vs.* growth in tissue culture (TC) media (media). Data are shown for one *C. glabrata* strain carrying pCU-ACO2-GFP and two independent strains carrying pCU-LYS21-GFP.](1675f4){#fig4}

![Expression from pCU-LYS21-GFP is increased in phagocytosed *C. glabrata. C. glabrata* strains carrying pCU-LYS21-GFP were grown in media only (left panels) or used to infect J774A.1 macrophage-like cells (right panels). After 2 hr, the cells were fixed and GFP expression was monitored by bright-field differential image contrast (DIC) and fluorescence microscopy. Merge panels were created by combining the bright-field and pseudo-colored GFP images using ImageJ. Scale bar is 10 μm.](1675f5){#fig5}

Nutritional regulation of the *MET3* promoter in *C. glabrata* {#s17}
--------------------------------------------------------------

The *MET3* promoter has been used successfully as a regulated promoter in *C. albicans*, and thus the plasmids pCU-MET3 and pCN-MET3 were constructed to allow for control of target gene expression in *C. glabrata* based on the presence or absence of Met and Cys in the media. The control of the *MET3* promoter in *C. glabrata* was monitored by flow cytometry on strains carrying the pCU-MET3 plasmid. In media containing excess Met and Cys (2 mM each), expression is repressed and the fluorescence profiles of pCU-MET3-GFP strains closely match the fluorescence profiles of strains carrying the pCU-MET3 empty vectors ([Figure 6, A and B](#fig6){ref-type="fig"}, "OFF"). In media lacking Met and Cys, the expression of GFP was greatly increased in strains carrying the pCU-MET3-GFP plasmids ([Figure 6](#fig6){ref-type="fig"}, "ON"). This tight regulation is seen in both log-phase and stationary-phase cultures of strains carrying pCU-MET3-GFP (compare [Figure 6A and 6B](#fig6){ref-type="fig"}). Similar results were seen for strains carrying the pCN-MET-GFP plasmids when grown in SED+Met+Cys−Ura or SED−Met−Cys−Ura media (data not shown).

![Fluorescence of *C. glabrata* strains carrying pCU-MET3 plasmids. Each panel depicts histograms of fluorescence for two *C. glabrata* strains containing the empty vectors (red and blue lines) and two *C. glabrata* strains containing GFP reporter vectors (green and orange lines). The median fluorescence value for each strain population is shown. "OFF" indicates the strains were grown in media containing 2 mM Met and Cys, which represses the *MET3* promoter. "ON" indicates the strains were grown in media lacking Met and Cys, which induces expression from the *MET3* promoter.](1675f6){#fig6}

Discussion {#s18}
==========

We chose to make a set of "constitutive" plasmids to facilitate cloning and expression of genes in *C. glabrata*. As evidenced by the flow cytometry data monitoring GFP expression in *C. glabrata* strains ([Figure 2](#fig2){ref-type="fig"}), the constitutive promoters are of three different strengths, with the rank order being *EGD2*pr\<*HHT2*pr\<*PDC1*pr.

We also designed versions of our centromeric plasmids with the *MET3* promoter. As in *C. albicans*, this promoter was tightly regulated by the presence or absence of methionine and cysteine in the media ([Figure 6](#fig6){ref-type="fig"}). In particular, cells growing exponentially in media supplemented with Met and Cys to repress the *MET3*pr appear to have shut-off all expression; the curves of the pCU-MET3-GFP curves are superimposed on empty vector controls in the far left panel of [Figure 6](#fig6){ref-type="fig"}. We note that repression of the *MET3* promoter seems a bit leakier in stationary phase cells. Vectors with the *MET3*pr will allow for tightly controlled expression of a target gene and may be appropriate to use for conditional control of essential genes.

Vectors also were constructed with the phagocytosis-induced promoters *ACO2* and *LYS21*. Expression from these promoters is low when cells are grown in laboratory media ([Figure 2](#fig2){ref-type="fig"}, [Figure 3](#fig3){ref-type="fig"}, [Figure 4](#fig4){ref-type="fig"}). However, 2 hr after engulfment within J774.A1 cultured macrophage cells, expression from the promoters increased. This increase expression is observed with both qRT-PCR and fluorescence microscopy ([Figure 4](#fig4){ref-type="fig"} and [Figure 5](#fig5){ref-type="fig"}), and we estimate a 24-fold to 59-fold increase of expression from these promoters after phagocytosis ([Figure 4](#fig4){ref-type="fig"}). Increased expression from the *ACO2*pr and *LYS21*pr after phagocytosis likely reflects a response to carbon and amino acid limitation in the phagolysosome ([@bib18]; [@bib16]). The leaky expression from the *LYS21*pr in stationary phase laboratory media ([Figure 3, panel E](#fig3){ref-type="fig"}) may reflect nutrient depletion in a saturated culture. Vectors containing *ACO2*pr or *LYS21*pr may prove useful to express a target gene in yeast specifically within the phagolysosome. Potentially, expression from the ACO2-GFP or LYS21-GFP vectors may serve as indirect indicators of phagocytosis. In the future, it may be possible to develop other plasmids that allow for variable expression within the macrophage or are specific to particular intracellular environments.

The "constitutive" promoters can be used to express proteins at different levels in standard laboratory media in log phase and stationary phase. We noticed that expression from the "constitutive" *PDC1* promoter decreased after phagocytosis by J774A.1 macrophage-like cells (data not shown). Although this is expected based on the transcriptional microarray data comparing phagocytosed and unphagocytosed *C. glabrata* ([@bib16]), it serves to emphasize that expression from the three "constitutive" promoters described in this work should be tested empirically when cells are grown under conditions other than the standard laboratory conditions monitored here.

The plasmids are stably maintained episomally, with no detectable integration into the genome and approximately 5--8% plasmid loss/generation as measured by a plating assay. The pCU vectors maintained at approximately 2 copies per cell; this is comparable with the plasmid copy numbers measured in haploid *S. cerevisiae* cells ([@bib14]). The pCN vectors were measured at 0.6--0.8 copies per cell, suggesting that a portion of the yeast cells grown under selection might have lost the pCN plasmid. This may reflect the ability of cells that have lost pCN plasmids to survive and replicate a small number of generations before dying. This is consistent with flow cytometry experiments measuring GFP expression showing that strains carrying pCN-XXX-GFP vectors have a fraction of the population that do not express GFP (data not shown). We conclude that though NAT selection allows overall maintenance of the plasmid, a small fraction of the cells in the culture no longer contain a plasmid, likely resulting from growth of cells that have lost the plasmid for a small number of divisions.

The standardized structure of the plasmids allow for easy modification. A gene of interest cloned into the MCS of one vector can be easily moved to another vector, which could allow researchers to adjust the strength of expression (by choosing a different promoter) or the selectable marker (by choosing the pCU or pCN backbones). For ease, the characteristics of the promoters described in this article are summarized in [Table S5](http://www.g3journal.org/lookup/suppl/doi:10.1534/g3.113.006908/-/DC1/TableS5.pdf). Additionally, the plasmids can be customized by introducing any promoter of choice into either the pCU or the pCN backbone, using a *Sac*I-*Xba*I restriction digest. This flexibility should allow investigators to introduce their favorite gene under control of its native promoter. The set of expression vectors described here can be used in many applications in *C. glabrata* and will expand the cloning tools available to the community.
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